郝清云

【摘要】 目的 觀察替格瑞洛聯(lián)合美托洛爾治療急性冠狀動(dòng)脈（冠脈）綜合征的臨床療效和護(hù)理效果。方法 88例急性冠脈綜合征患者， 隨機(jī)將其分為對照組和觀察組， 每組44例。對照組患者行替格瑞洛治療， 觀察組患者在對照組的基礎(chǔ)上增加美托洛爾治療。觀察并對比兩組治療前后C反應(yīng)蛋白（CRP）、肌酸激酶-同工酶（CK-MB）、肌鈣蛋白T（cTnT）、胸痛總積分水平及心律失常的發(fā)生情況， 觀察并對比兩組患者治療效果。結(jié)果 觀察組患者的臨床治療總有效率為95.45%， 高于對照組的81.82%， 差異具有統(tǒng)計(jì)學(xué)意義（χ2=4.0615， P=0.0438<0.05）。治療前， 兩組患者CRP水平、CK-MB、cTnT、胸痛總積分及心律失常發(fā)生率比較， 差異無統(tǒng)計(jì)學(xué)意義（P>0.05）;治療后， 兩組患者CRP水平、CK-MB水平、cTnT水平及胸痛總積分、心律失常發(fā)生率均低于治療前， 且觀察組低于對照組， 差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 對急性冠脈綜合征患者應(yīng)用替格瑞洛聯(lián)合美托洛爾治療， 相較于單一替格瑞洛治療療效更為顯著， 可有效抑制患者心肌收縮， 降低猝死率， 值得臨床推廣。

【關(guān)鍵詞】 替格瑞洛;美托洛爾;急性冠狀動(dòng)脈綜合征;臨床療效

DOI：10.14163/j.cnki.11-5547/r.2019.17.049

Observation on clinical efficacy of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome? ?HAO Qing-yun. Shandong Tengzhou Workers Hospital， Tengzhou 277500， China

【Abstract】 Objective? ?To observe the clinical efficacy and nursing effect of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome. Methods? ?A total of 88 patients with acute coronary syndrome were randomly divided into control group and observation group， with 44 cases in each group. The control group was treated with ticagrelor， and the observation group was treated with metoprolol on the basis of the control group. Observation and comparison were made on C-reactive protein （CRP）， creatine kinase-MB （CK-MB）， troponin T （cTnT）， total score of chest pain and occurrence of arrhythmia before and after treatment and treatment effect between the two groups. Results? ?The observation group had higher total effective rate of clinical treatment as 95.45% than 81.82% in the control group， and the difference was statistically significant （χ2=4.0615， P=0.0438<0.05）. Before treatment， both groups had no statistically significant difference in CRP， CK-MB， cTnT， total score of chest pain and incidence of arrhythmia （P>0.05）. After treatment， both groups had lower CRP， CK-MB， cTnT， total score of chest pain and incidence of arrhythmia than those before treatment， and the observation group was lower than the control group. Their difference was statistically significant （P<0.05）. Conclusion? ?Ticagrelor combined with metoprolol is more effective than single ticagrelor in the treatment of acute coronary syndrome， and it can effectively inhibit myocardial contraction and reduce sudden death rate. It is worthy of clinical promotion.

【Key words】 Ticagrelor; Metoprolol; Acute coronary syndrome; Clinical efficacy